Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
Clinical trial NCT02652260 · COMPLETED
Trial details
- NCT number
- NCT02652260
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-04
- Primary completion
- 2018-08-14
- Enrollment
- 86
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.